USFDA nod may boost Aurobindo Pharma

| Updated on October 24, 2019


Aurobindo Pharma has received final approval from the US Food & Drug Administration to manufacture Guaifenesin extended-release tablets, 600 mg and 1,200 mg. The product is expected to launch during the fourth quarter of FY20. The product has an estimated market size of $301 million for the 12 months ending July 2019. Aurobindo now has a total of 419 ANDA approvals (392 final approvals, including 21 from Aurolife Pharma LLC and 27 tentative approvals) from the USFDA.

Published on October 25, 2019

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like